Wall Street Zen Downgrades MaxCyte (NASDAQ:MXCT) to Sell

MaxCyte (NASDAQ:MXCT) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MaxCyte in a report on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, MaxCyte presently has a consensus rating of “Hold” and a consensus target price of $7.00.

MaxCyte Price Performance

Shares of MaxCyte stock opened at $0.78 on Friday. The stock has a market cap of $83.20 million, a price-to-earnings ratio of -1.77 and a beta of 1.22. The firm’s 50-day moving average is $1.05 and its 200 day moving average is $1.38. MaxCyte has a 1 year low of $0.64 and a 1 year high of $3.58.

Institutional Investors Weigh In On MaxCyte

Several institutional investors have recently modified their holdings of MXCT. Prudential Financial Inc. purchased a new position in MaxCyte in the 2nd quarter worth about $26,000. State of Wyoming purchased a new stake in shares of MaxCyte during the 2nd quarter valued at about $38,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of MaxCyte during the 2nd quarter valued at about $40,000. Kwmg LLC grew its stake in shares of MaxCyte by 75.8% in the third quarter. Kwmg LLC now owns 25,833 shares of the company’s stock worth $41,000 after acquiring an additional 11,135 shares during the period. Finally, Jain Global LLC bought a new stake in shares of MaxCyte in the fourth quarter worth approximately $45,000. 68.81% of the stock is owned by hedge funds and other institutional investors.

MaxCyte Company Profile

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.